Development Of Clinical Algorithms To Diagnose And Predict Prognosis Of Food Allergy
Funder
National Health and Medical Research Council
Funding Amount
$136,636.00
Summary
Australia has the highest rate of food allergy internationally. Despite ongoing research into the area, there is currently no cure, with patient avoidance the most effective mode for the prevention of food allergy. A food challenge still the gold standard for food allergy diagnosis, and although definitive, is associated with a risk of anaphylaxis. My research aims to identify the biological differences between active disease and being healthy to develop novel diagnostic methods for food allergy
Novel Methods To Diagnose Clinical Egg Allergy And Predict Prognostic Outcomes
Funder
National Health and Medical Research Council
Funding Amount
$318,768.00
Summary
Australia has the highest rate of food allergy in the world. Despite ongoing research into the area, there is currently no cure, with patient avoidance the most effective way to prevent food reactions. A food challenge is the gold standard for food allergy diagnosis. Although definitive, it is associated with a risk of anaphylaxis. My research aims to identify the biological differences between having food allergy and not having food allergy to develop novel diagnostic methods.
Long Term Outcomes Of Infant Lung Function In Cystic Fibrosis
Funder
National Health and Medical Research Council
Funding Amount
$509,456.00
Summary
We have shown that babies with cystic fibrosis (CF) who are apparently well can still have lung problems. As lung disease is the major cause of death in CF we need ways to monitor the condition in babies, identify those at greatest risk of lung changes and predict which children should receive newer treatments. We have developed a unique program for the measurement of lung function in babies. We now aim to find out the long term consequences of lung function changes detected in infants with CF.
Bio-molecular Studies For Improved Diagnosis And Management Of Australian Children With Fish Allergy
Funder
National Health and Medical Research Council
Funding Amount
$496,602.00
Summary
Allergy to fish among children is often life-long and emerging as a significant healthcare issue worldwide, while management of fish allergy is challenging due to the lack of reliable diagnostic assays. This research grant will lead to the development of novel diagnostics for fish allergy in Australia, addressing aspects of the worldwide food allergy epidemic and forms the ideal platform for the study of fish specific allergens, generating novel knowledge for greatly improved patient management.
Improving The Long-term Quality Of Life For Preterm Children
Funder
National Health and Medical Research Council
Funding Amount
$638,517.00
Summary
My vision is to improve the long-term quality of life of preterm children (<37 weeks’ gestation), with a specific focus on those born very preterm (VP; <32 weeks’ gestation). To achieve this goal my research has two broad and related aims: 1) Determine the neurological and socio-environmental mechanisms leading to impairments in preterm children; and 2) Develop and assess the efficacy of perinatal and early intervention programs for preterm children.
Neurobehaviour Between Birth And 40 Weeks In Infants Born
Funder
National Health and Medical Research Council
Funding Amount
$832,215.00
Summary
Very preterm infants (born at <30 weeks’ gestation) are at risk of long term developmental problems with 50% having cognitive, motor or behavioural problems. This study will examine, for the first time, neurobehavioral development of very preterm infants from birth so that we can describe neurobehaviour for a given gestation from birth to term equivalent age, and explore how it relates to brain growth or injury and to neurodevelopmental outcome at two years’ corrected age.
Australasian Cerebral Palsy Clinical Trials Network (AusCP-CTN): Optimising Interventions And Effective Services For Children With Cerebral Palsy
Funder
National Health and Medical Research Council
Funding Amount
$2,499,287.00
Summary
Cerebral Palsy (CP) is common and disability can be progressive so the heathcare burden is immense (0.14% GDP). Our Clinical trials network will improve early detection and develop new interventions to improve physical, cognitive and health outcomes for children with CP and their families. Recruitment from the national CP Register will address clinically important questions and test implementation of effective treatments. New Clinical Practice Guidelines will ensure translation internationally.